Scandinavian ChemoTech receives its first order from their new distributor in India

Today Scandinavian ChemoTech received its first order worth €3.300 from their new distributor Horizon Medical Technologies in India.

The distribution agreement was signed in December 2019 and the order placed today is for treatment kits dedicated to Horizons launch of IQwave™ Tumour Specific Electroporation.

Horizon is a distributor with more than 15 years of experience in distribution and business development in the field of medical devices. They have successfully worked with Dräger, Smith Medical, Zimmer Bio Met, among others and has more than 20 private hospitals and hospital groups in northern India as their customers and to which they will now start marketing IQwave™ and Tumour Specific Electroporation™.

“It’s great that the collaboration with Horizon is following the agreed plan. We now have a couple of intensive months ahead of us supporting them in reaching their expected targets. “, says Mohan Frick CEO. 

For further information please contact:

Mohan Frick, Co-Founder and CEO

+46 (0)10-218 93 00

info@chemotech.se

 

 

Scandinavian ChemoTech AB (publ)

ChemoTech is a Swedish medical technology company based in Lund that has developed a patented technology platform to offer cancer patients access to a new treatment alternative, tumour specific electroporation, available for treatment of both for humans and animals. There are a large number of cancer patients whose tumours for various reasons cannot be treated by conventional methods but where tumour specific electroporation can be a solution. Therefore, the company continuously evaluates new opportunities and areas of application for the technology. ChemoTech's shares (CMOTEC B) are listed on Nasdaq First North Growth Market in Stockholm and Västra Hamnen Corporate Finance AB is the company's Certified Adviser. Read more at: www.chemotech.se.

Subscribe

Documents & Links